Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Tricyclic antipsychotics and antidepressants can inhibit α5-containing GABAA receptors by two distinct mechanisms.
Bampali K
,
Koniuszewski F
,
Silva LL
,
Rehman S
,
Vogel FD
,
Seidel T
,
Scholze P
,
Zirpel F
,
Garon A
,
Langer T
,
Willeit M
,
Ernst M
.
???displayArticle.abstract???
BACKGROUND AND PURPOSE: Many psychotherapeutic drugs, including clozapine, display polypharmacology and act on GABAA receptors. Patients with schizophrenia show alterations in function, structure and molecular composition of the hippocampus, and a recent study demonstrated aberrant levels of hippocampal α5 subunit-containing GABAA receptors. The purpose of this study is to investigate the effects of tricyclic compounds on α5 subunit-containing receptor subtypes.
EXPERIMENTAL APPROACH: Functional studies of effects by seven antipsychotic and antidepressant medications were performed in several GABAA receptor subtypes by two-electrode voltage-clamp electrophysiology using Xenopus laevis oocytes. Computational structural analysis was employed to design mutated constructs of the α5 subunit, probing a novel binding site. Radioligand displacement data complemented the functional and mutational findings.
KEY RESULTS: The antipsychotic drugs clozapine and chlorpromazine exerted functional inhibition on multiple GABAA receptor subtypes, including those containing α5-subunits. Based on a chlorpromazine binding site observed in a GABA-gated bacterial homologue, we identified a novel site in α5 GABAA receptor subunits and demonstrate differential usage of this and the orthosteric sites by these ligands.
CONCLUSION AND IMPLICATIONS: Despite high molecular and functional similarities among the tested ligands, they reduce GABA currents by differential usage of allosteric and orthosteric sites. The chlorpromazine site we describe here is a new potential target for optimizing antipsychotic medications with beneficial polypharmacology. Further studies in defined subtypes are needed to substantiate mechanistic links between the therapeutic effects of clozapine and its action on certain GABAA receptor subtypes.
Alexander,
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein-coupled receptors.
2021, Pubmed
Alexander,
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein-coupled receptors.
2021,
Pubmed
Alexander,
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Ion channels.
2021,
Pubmed
Asproni,
Synthesis and pharmacological evaluation of 1-[(1,2-diphenyl-1H-4-imidazolyl)methyl]-4-phenylpiperazines with clozapine-like mixed activities at dopamine D(2), serotonin, and GABA(A) receptors.
2002,
Pubmed
,
Xenbase
Atack,
L-655,708 enhances cognition in rats but is not proconvulsant at a dose selective for alpha5-containing GABAA receptors.
2006,
Pubmed
Attard,
Comparative effectiveness of atypical antipsychotics in schizophrenia: what have real-world trials taught us?
2012,
Pubmed
Besnard,
Automated design of ligands to polypharmacological profiles.
2012,
Pubmed
Charych,
GABA(A) receptors and their associated proteins: implications in the etiology and treatment of schizophrenia and related disorders.
2009,
Pubmed
Curtis,
Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers.
2018,
Pubmed
Delini-Stula,
Antipsychotic effects of bretazenil, a partial benzodiazepine agonist in acute schizophrenia--a study group report.
1996,
Pubmed
Etherington,
Selective inhibition of extra-synaptic α5-GABAA receptors by S44819, a new therapeutic agent.
2017,
Pubmed
Gill,
The role of α5 GABAA receptor agonists in the treatment of cognitive deficits in schizophrenia.
2014,
Pubmed
Glykys,
Which GABA(A) receptor subunits are necessary for tonic inhibition in the hippocampus?
2008,
Pubmed
Hawkins,
Comparison of shape-matching and docking as virtual screening tools.
2007,
Pubmed
Hawkins,
Conformer generation with OMEGA: algorithm and validation using high quality structures from the Protein Databank and Cambridge Structural Database.
2010,
Pubmed
Huhn,
Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis.
2019,
Pubmed
Kim,
Shared structural mechanisms of general anaesthetics and benzodiazepines.
2020,
Pubmed
Knust,
The discovery and unique pharmacological profile of RO4938581 and RO4882224 as potent and selective GABAA alpha5 inverse agonists for the treatment of cognitive dysfunction.
2009,
Pubmed
Korpi,
Subtype specificity of gamma-aminobutyric acid type A receptor antagonism by clozapine.
1995,
Pubmed
Lieberman,
Hippocampal dysfunction in the pathophysiology of schizophrenia: a selective review and hypothesis for early detection and intervention.
2018,
Pubmed
Liu,
Cryo-EM structure of the human α5β3 GABAA receptor.
2018,
Pubmed
Lodge,
Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia.
2011,
Pubmed
Marques,
GABA-A receptor differences in schizophrenia: a positron emission tomography study using [11C]Ro154513.
2021,
Pubmed
Masiulis,
GABAA receptor signalling mechanisms revealed by structural pharmacology.
2019,
Pubmed
Michel,
Clozapine inhibits synaptic transmission at GABAergic synapses established by ventral tegmental area neurones in culture.
2000,
Pubmed
Mozrzymas,
Chlorpromazine inhibits miniature GABAergic currents by reducing the binding and by increasing the unbinding rate of GABAA receptors.
1999,
Pubmed
Nakahara,
Hippocampal subregion abnormalities in schizophrenia: A systematic review of structural and physiological imaging studies.
2018,
Pubmed
Nys,
Allosteric binding site in a Cys-loop receptor ligand-binding domain unveiled in the crystal structure of ELIC in complex with chlorpromazine.
2016,
Pubmed
,
Xenbase
Olsen,
International Union of Pharmacology. LXX. Subtypes of gamma-aminobutyric acid(A) receptors: classification on the basis of subunit composition, pharmacology, and function. Update.
2008,
Pubmed
Pirker,
GABA(A) receptors: immunocytochemical distribution of 13 subunits in the adult rat brain.
2000,
Pubmed
Poli,
Conformational Sampling of Small Molecules With iCon: Performance Assessment in Comparison With OMEGA.
2018,
Pubmed
Puia,
Neurosteroids act on recombinant human GABAA receptors.
1990,
Pubmed
Puthenkalam,
Structural Studies of GABAA Receptor Binding Sites: Which Experimental Structure Tells us What?
2016,
Pubmed
Rahman,
GABA-site antagonism and pentobarbital actions do not depend on the alpha-subunit type in the recombinant rat GABA receptor.
2006,
Pubmed
,
Xenbase
Schwartz,
Inhibition of the GABA receptor-gated chloride ion channel in brain by noncompetitive inhibitors of the nicotinic receptor-gated cation channel.
1988,
Pubmed
Seeman,
Brain dopamine receptors.
1980,
Pubmed
Seeman,
Targeting the dopamine D2 receptor in schizophrenia.
2006,
Pubmed
Sigel,
The Benzodiazepine Binding Sites of GABAA Receptors.
2018,
Pubmed
Simeone,
Defined concatenated α6α1β3γ2 GABAA receptor constructs reveal dual action of pyrazoloquinolinone allosteric modulators.
2019,
Pubmed
Simeone,
Molecular tools for GABAA receptors: High affinity ligands for β1-containing subtypes.
2017,
Pubmed
,
Xenbase
Skilbeck,
The effects of antipsychotic drugs on GABAA receptor binding depend on period of drug treatment and binding site examined.
2007,
Pubmed
Sperk,
GABA(A) receptor subunits in the rat hippocampus I: immunocytochemical distribution of 13 subunits.
1997,
Pubmed
Squires,
GABAA receptor blockers reverse the inhibitory effect of GABA on brain-specific [35S]TBPS binding.
1987,
Pubmed
Squires,
Antidepressants and metabolites that block GABAA receptors coupled to 35S-t-butylbicyclophosphorothionate binding sites in rat brain.
1988,
Pubmed
Squires,
A review of evidence for GABergic predominance/glutamatergic deficit as a common etiological factor in both schizophrenia and affective psychoses: more support for a continuum hypothesis of "functional" psychosis.
1991,
Pubmed
Squires,
Mono N-aryl ethylenediamine and piperazine derivatives are GABAA receptor blockers: implications for psychiatry.
1993,
Pubmed
Squires,
Clozapine and some other antipsychotic drugs may preferentially block the same subset of GABA(A) receptors.
1997,
Pubmed
Squires,
Clozapine and several other antipsychotic/antidepressant drugs preferentially block the same 'core' fraction of GABA(A) receptors.
1998,
Pubmed
Squires,
Clozapine's antipsychotic effects do not depend on blockade of 5-HT3 receptors.
1999,
Pubmed
Squires,
Additivities of compounds that increase the numbers of high affinity [3H]muscimol binding sites by different amounts define more than 9 GABA(A) receptor complexes in rat forebrain: implications for schizophrenia and clozapine research.
2000,
Pubmed
Tauscher,
Significant dissociation of brain and plasma kinetics with antipsychotics.
2002,
Pubmed
Virtanen,
SciPy 1.0: fundamental algorithms for scientific computing in Python.
2020,
Pubmed
Wohlfarth,
Enhanced neurosteroid potentiation of ternary GABA(A) receptors containing the delta subunit.
2002,
Pubmed
Wolber,
Efficient overlay of small organic molecules using 3D pharmacophores.
2006,
Pubmed
Wolber,
LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters.
2005,
Pubmed
Wongsamitkul,
α subunits in GABAA receptors are dispensable for GABA and diazepam action.
2017,
Pubmed
,
Xenbase
Xu,
GABAergic inhibitory neurons as therapeutic targets for cognitive impairment in schizophrenia.
2018,
Pubmed
Yada,
The relationship between plasma clozapine concentration and clinical outcome: a cross-sectional study.
2021,
Pubmed
Yokota,
The effects of neuroleptics on the GABA-induced Cl- current in rat dorsal root ganglion neurons: differences between some neuroleptics.
2002,
Pubmed
